bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
Company profile
Ticker
BTAI
Exchange
Website
CEO
Vimal Mehta
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
OnkosXcel Therapeutics, LLC • OnkosXcel Employee Holdings, LLC ...
BTAI stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
22 Apr 24
PRE 14A
Preliminary proxy
19 Apr 24
8-K
Regulation FD Disclosure
10 Apr 24
S-8
Registration of securities for employees
3 Apr 24
8-K
Entry into a Material Definitive Agreement
25 Mar 24
424B5
Prospectus supplement for primary offering
25 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
12 Mar 24
8-K
Regulation FD Disclosure
14 Feb 24
8-K
Entry into a Material Definitive Agreement
12 Feb 24
Transcripts
BTAI
Earnings call transcript
2023 Q4
12 Mar 24
BTAI
Earnings call transcript
2023 Q3
14 Nov 23
BTAI
Earnings call transcript
2023 Q2
14 Aug 23
BTAI
Earnings call transcript
2023 Q1
8 May 23
BTAI
Earnings call transcript
2022 Q4
9 Mar 23
BTAI
Earnings call transcript
2022 Q3
10 Nov 22
BTAI
Earnings call transcript
2022 Q2
9 Aug 22
BTAI
Earnings call transcript
2022 Q1
9 May 22
BTAI
Earnings call transcript
2021 Q4
10 Mar 22
BTAI
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
Vincent O'Neill
8 Apr 24
4
Vimal Mehta
8 Apr 24
4
Richard I Steinhart
8 Apr 24
4
Matthew T. Wiley
8 Apr 24
4
Javier Rodriguez
8 Apr 24
4
Frank Yocca
8 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 89.96 mm | 89.96 mm | 89.96 mm | 89.96 mm | 89.96 mm | 89.96 mm |
Cash burn (monthly) | 12.53 mm | 11.86 mm | 16.10 mm | 17.07 mm | 12.53 mm | 13.90 mm |
Cash used (since last report) | 86.31 mm | 81.73 mm | 110.91 mm | 117.58 mm | 86.31 mm | 95.75 mm |
Cash remaining | 3.65 mm | 8.23 mm | -20.95 mm | -27.62 mm | 3.65 mm | -5.79 mm |
Runway (months of cash) | 0.3 | 0.7 | -1.3 | -1.6 | 0.3 | -0.4 |
Institutional ownership, Q3 2023
73.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 86 |
Opened positions | 20 |
Closed positions | 26 |
Increased positions | 21 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 26.28 bn |
Total shares | 27.29 mm |
Total puts | 264.50 k |
Total calls | 367.20 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BioXcel | 8.55 mm | $26.67 mm |
BioXcel | 8.55 mm | $163.24 mm |
FMR | 2.70 mm | $6.83 bn |
BLK Blackrock | 1.30 mm | $3.28 bn |
Vanguard | 1.22 mm | $3.09 bn |
AMP Ameriprise Financial | 668.37 k | $1.69 bn |
Two Sigma Investments | 432.47 k | $1.09 bn |
Geode Capital Management | 423.12 k | $1.07 bn |
STT State Street | 409.86 k | $1.04 bn |
Beacon Pointe Advisors | 301.74 k | $763.39 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Apr 24 | Matthew T. Wiley | Common Stock | Sell | Dispose S | No | Yes | 2.6351 | 1,008 | 2.66 k | 2,992 |
4 Apr 24 | Yocca Frank | Common Stock | Sell | Dispose S | No | Yes | 2.635 | 1,067 | 2.81 k | 12,763 |
4 Apr 24 | Javier Rodriguez | Common Stock | Sell | Dispose S | No | Yes | 2.6358 | 1,012 | 2.67 k | 7,672 |
4 Apr 24 | Mehta Vimal | Common Stock | Sell | Dispose S | No | Yes | 2.6247 | 4,439 | 11.65 k | 43,564 |
4 Apr 24 | Mehta Vimal | Common Stock | Sell | Dispose S | No | Yes | 2.62 | 829 | 2.17 k | 48,003 |
4 Apr 24 | Richard I Steinhart | Common Stock | Sell | Dispose S | No | Yes | 2.635 | 1,069 | 2.82 k | 4,765 |
15 Mar 24 | Matthew T. Wiley | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,000 | 0.00 | 3,000 |
15 Mar 24 | Matthew T. Wiley | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 3,000 | 0.00 | 9,000 |
15 Mar 24 | Yocca Frank | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,250 | 0.00 | 13,830 |
15 Mar 24 | Yocca Frank | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,250 | 0.00 | 6,750 |
News
BioXcel Therapeutics Announces Late-Breaking Abstract On Preliminary Findings From Phase 2 Investigator-Sponsored Trial Of BXCL701 And KEYTRUDA In Metastatic Pancreatic Ductal Adenocarcinoma Selected For Presentation At 2024 ASCO Annual Meeting
24 Apr 24
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
23 Apr 24
BioXcel Therapeutics Reveals Plan For Evaluating BXCL501 In The At-Home Setting To Expand Its Market Potential
22 Apr 24
BioXcel Therapeutics Announces $25M Registered Direct Offering
25 Mar 24
BioXcel Therapeutics Reported That The European Patent Office Granted The Company's European Patent Covering The Use Of Dexmedetomidine Administered Sublingually To Treat Agitation In Individuals With Dementia
15 Mar 24
Press releases
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
24 Apr 24
Treatment AI (CSE: TRUE) Unveils New AI-Powered Solutions Revolutionizing Medical Education
18 Apr 24
Unleashing AI in Healthcare: The Game-Changing Partnership Between Treatment AI (CSE: TRUE) and aiXplain concurrent with Federal Momentum
16 Apr 24
AI Transforms Healthcare Stocks in 2024: Revolutionizing Medicine Across the Globe
11 Apr 24
Canada's Strategic Move Towards AI: An Investor and Trader's Perspective
9 Apr 24